Member Info for Malpenn

I am getting carries away.. could GC vote, if so I wonder how he voted !!

What a result !!! JB's planning is coming together. Every step he laid out...

Halifax has been NT for the past few mins to buy

London, UK 23 September 2020: ValiRx Plc (AIM: VAL), the clinical stage biotechnology company, notes the recent movement in its share price and confirms as notified on 7 September 2020, it still expects to receive and notify the headline VAL 201 trial results by 30 September 2020 as stated in the half year results notified on 7 September 2020, extracts of which as set out below:-

https://www.sharebuyers.co.uk/shares/supplyme-says-investors-didnt-understand-its-bank-announcement-so-heres-5-key-points-to-take-note-of/

New bank will be worldwide funding engine not just funding for Italian market...

https://www.proactiveinvestors.co.uk/companies/amp/news/929672?__twitter_impression=true

09.00 - 10.00
HOW DIGITAL FINANCING IS CHANGING. FROM INVOICE DISCOUNTING TO INVENTORY FINANCE, TO MEDIUM-TERM CREDIT
Live conference on Class CNBC (Sky channel 507)

Participants:

Daniele Loro , CEO and Co-Founder, Prestiamoci Spa

Isidoro Lucciola , President, TeamSystem Financial Value Chain and TeamSystem Capital @ Work SGR

Tiziana Marongiu , Chief Business Development Officer, Believe me

Michele Ronchi , CEO, FIFTY srl

Roberto Tarricone , Head of Strategic Marketing, MF Centrale Risk

Enrico Viganò , CEO & Founder, FinDynamic

Alessandro Zamboni, CEO, Supply @ ME Capital PLC

https://www.classagora.it/eventi/mf-digital-week-2020

#syme
Interview today with @Alessan62698938 on @Share_Talk

Also @Alessan62698938 speaking live on #SKY 30th Sep

HOW DIGITAL FINANCING IS CHANGING. FROM INVOICE DISCOUNTING TO INVENTORY FINANCE, TO MEDIUM-TERM CREDIT

Live conference (Sky channel 507) https://t.co/1ShsXnkUlG https://t.co/Qqx9K3bHnc

https://mobile.twitter.com/AimHardy/status/1306492069641322496

I am hoping for a partnership with a US pharma as part of the announcement and given their focus on US investors, it wouldnt surprise me if it was a afternoon RNS if it was good news to coincide with US market times.

Just a thought..

The communication from 4D certainly sounds positive in terms of expected results from the IBS trial. I just wondered if anyone has taken a look at the following file posted in October 2019, I am certainly not a scientist but it certainly seems positive again.

4D pharma presents additional analysis of Blautix Phase Ib study in IBS

Projected was the 25th

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that members of management will host a virtual investor event following the European Society for Medical Oncology (ESMO) Virtual Congress 2020 where they will highlight select datasets and give an overview of the company’s broad oncology portfolio on Sept. 22 at 8:00 am EDT.

Investors, analysts, members of the media and the general public are invited to listen to a live audio webcast of the presentation at https://www.merck.com/investor-relations/events-and-presentations/.

"This is a true first in the field of live biotherapeutics. 4D has been able to produce an orally delivered live biotherapeutic, and generate meaningful data surrounding mechanism of action, and safety and tolerability, with great efficiency,” said chief executive Duncan Peyton

https://www.proactiveinvestors.co.uk/companies/news/128345/4d-pharma-s-first-in-man-study-shows-encouraging-symptom-improvement-128345.html

https://verdant-news.com/news/6852/americas-ibs-treatment-market-capacity-production-revenue-price-and-gross-margin-2020-to-2026-post-impact-of-worldwide-covid-19-spread-analysis/

https://news.sky.com/story/pms-operation-moonshot-plan-can-be-done-says-chinese-company-behind-new-30-minute-covid-19-test-12072985

MMs are doing a count down to 0.. then take off !!!

I am also going to suggest that an article like that is unlikely to have been released if the company was able to announce poor results of the IBS phase results.